EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Performance of PREMM5, clinical criteria, and immunohistochemistry for MMR proteins in genetic risk assessment of Mexican patients with colorectal cancer

José Luis Rodríguez-Olivares iD, Dione Aguilar-Y-Méndez, Tamara N Kimball, Pamela Rivero-García iD, Javier Rios-Valencia, Sandra Santuario-Facio, Augusto Rojas-Martinez iD, Rocío Ortiz-López, Angélica Leticia Barraza-Arellano, Alejandro Aranda-Gutierrez, Jazmín Arteaga-Vazquez, Héctor De-La-Mora-Molina und 4 weitere

PLOS One · 04.08.2026 · 21 (8) · e0354795

DOI: 10.1371/journal.pone.0354795 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 04.08.2026. Verfasst von José Luis Rodríguez-Olivares und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. Hauptthemen laut MEDLINE: Colorectal Neoplasms, DNA Mismatch Repair. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Breast Cancer Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

All individuals with colorectal cancer (CRC) should undergo genetic cancer risk assessment given its implications for personalized treatment, surveillance, risk-reduction strategies, and cascade testing. Universal screening using immunohistochemistry (IHC) for mismatch repair (MMR) proteins in tumor tissue, when combined with clinical criteria, is essential for identifying individuals at higher risk for carrying germline pathogenic variants (PVs) in resource limited countries. Patients and Methods The spectrum of PVs in cancer susceptibility genes was characterized using NGS multigene panel assays among selected patients with CRC at two centers in Mexico. Germline genetic testing was used as the reference standard to evaluate the diagnostic accuracy of the referral criteria.

Results

From September 2018 to October 2024, 208 patients were enrolled. The median age at diagnosis was 45.0 years; 52.4% were women, 48.6% had deficient-MMR CRC, and 38.0% reported family history of CRC. Germline PVs were identified in 32.2% (n = 67); of these, 77.6% (n = 52) had Lynch syndrome (30 MLH1 , 14 MSH2 , 6 MSH6 , and 2 PMS2 ), while 22.4% (n = 15) harbored PVs in other genes (4 ATM , 3 BRCA1 , 3 CHEK2 , 2 TP53 , 1 BRCA2 , 1 BRIP1 , and 1 PALB2 ). Additionally, one individual harbored a monoallelic PV in MUTYH . The Amsterdam II criteria demonstrated the highest specificity (Sensitivity 56.0%, Specificity 91.9%), while the revised Bethesda criteria (Sensitivity 98.1%, Specificity 19.9%) and IHC for MMR proteins (Sensitivity 91.2%, Specificity 68.7%) exhibited high sensitivity. The area under the ROC curve for PREMM5 was 0.822 (95% CI 0.746–0.898).

Conclusion

PREMM5, Revised Bethesda criteria and IHC for MMR proteins effectively prioritized patients eligible for germline genetic testing in resource-limited settings. The performance of PREMM5 in this Mexican cohort was comparable to findings reported in validation studies within other populations. Considering the spectrum of PVs identified, employing a multigene panel test is recommended for Mexican patients with CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsDNA Mismatch RepairHumansFemaleMexicoMiddle AgedMaleImmunohistochemistryGerm-Line MutationRisk AssessmentGenetic Predisposition to DiseaseAdultGenetic TestingAgedDNA-Binding Proteins

Substanzen

DNA-Binding Proteins

Autor:innen und Institutionen

  • Department of Hematology and Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • Hospital Zambrano Hellion Tec Salud, San Pedro Garza García, Mexico.
  • Tecnológico de Monterrey. Escuela de Medicina y Ciencias de la Salud. Monterrey, Mexico.
  • Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
  • Department of Medical Genetics, Instituto Nacional De Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • Department of Pathology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

ORCID-Profile: José Luis Rodríguez-Olivares, Pamela Rivero-García, Augusto Rojas-Martinez, Yanin Chávarri-Guerra

Förderung

  • Breast Cancer Research Foundation

Zitieren

APA

Rodríguez-Olivares, J. L., Aguilar-Y-Méndez, D., Kimball, T. N., Rivero-García, P., Rios-Valencia, J., Santuario-Facio, S., Rojas-Martinez, A., Ortiz-López, R., Barraza-Arellano, A. L., Aranda-Gutierrez, A., Arteaga-Vazquez, J., De-La-Mora-Molina, H., Herzog, J., Jeter, J. M., Weitzel, J. N., & Chávarri-Guerra, Y. (2026). Performance of PREMM5, clinical criteria, and immunohistochemistry for MMR proteins in genetic risk assessment of Mexican patients with colorectal cancer. PLOS One, 21(8), e0354795. https://doi.org/10.1371/journal.pone.0354795

Vancouver

Rodríguez-Olivares JL, Aguilar-Y-Méndez D, Kimball TN, Rivero-García P, Rios-Valencia J, Santuario-Facio S, et al. Performance of PREMM5, clinical criteria, and immunohistochemistry for MMR proteins in genetic risk assessment of Mexican patients with colorectal cancer. PLOS One. 2026;21(8):e0354795. doi:10.1371/journal.pone.0354795

BibTeX
@article{RodrguezOlivares2026,
  author = {Rodríguez-Olivares, José Luis and Aguilar-Y-Méndez, Dione and Kimball, Tamara N and Rivero-García, Pamela and Rios-Valencia, Javier and Santuario-Facio, Sandra and Rojas-Martinez, Augusto and Ortiz-López, Rocío and Barraza-Arellano, Angélica Leticia and Aranda-Gutierrez, Alejandro and Arteaga-Vazquez, Jazmín and De-La-Mora-Molina, Héctor and Herzog, Josef and Jeter, Joanne M and Weitzel, Jeffrey N and Chávarri-Guerra, Yanin},
  title = {Performance of PREMM5, clinical criteria, and immunohistochemistry for MMR proteins in genetic risk assessment of Mexican patients with colorectal cancer},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {8},
  pages = {e0354795},
  doi = {10.1371/journal.pone.0354795}
}
Kostenlos starten →